Clinical trials: High-Risk Cancer
Glioma, Glioblastoma
Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier (BBB) Disruption
The purpose of this study is to evaluate the safety of the ExAblate Model 4000 Type 2 used as a tool to disrupt the BBB (blood brain barrier) in patients with high grade glioma undergoing standard of care therapy.
- Trial name
- NCT03551249
- Testing
- Focused ultrasound (FUS)
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- InSightec
Leukemia
Chemotherapy Followed by Peripheral Stem Cell Transplantation And Biological Therapy in Treating Patients With Chronic Myelogenous Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing.
- Trial name
- NCT00005948
- Testing
- aldesleukin, recombinant interferon alfa, sargramostim
- Where
- 2 sites in United States
- Sponsor
- Fred Hutchinson Cancer Center
Patients With Uterine Fibroids Receiving HIFUA Treatment ,and Can Undergo Regular Follow-up
The Clinical Application of Ultramicro-flow Technique in the Treatment of Benign Uterine Tumors With High-intensity Focused Ultrasound
High intensity focused ultrasound ablation (HIFUA) is a new non-invasive treatment method for uterine tumors. Traditionally, nuclear magnetic resonance imaging (NMRI), also known as magnetic resonance imaging (MRI), is used as…
- Trial name
- NCT06435663
- Testing
- Different methods of efficacy evaluation
- Where
- China
- Volunteers
- 30 people
- Sponsor
- The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Rectal Cancer, Adenocarcinoma
HDR Endorectal Brachytherapy With 3D-Printed Guidance and Local Shielding for Rectal Cancer Organ Preservation
This prospective, single-center, single-arm phase II study will evaluate the efficacy, safety, and technical feasibility of an organ-preserving radiotherapy strategy for patients with localized rectal adenocarcinoma who are…
- Trial name
- NOM-HDR-W (NCT07786493)
- Testing
- High-Dose-Rate Endorectal Brachytherapy
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Lung Cancer
Chemotherapy Followed by Peripheral Stem Cell or Bone Marrow Transplant Compared With Chemotherapy Alone in Treating Patients With Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving chemotherapy with peripheral stem cell transplant or bone marrow transplant may allow the doctor to…
- Trial name
- NCT00011921
- Testing
- filgrastim, carboplatin, epirubicin hydrochloride
- Where
- Switzerland
- Volunteers
- 430 people
- Sponsor
- EBMT Solid Tumors Working Party
Breast Cancer, HR+/HER2- Breast Cancer
To Evaluate the Efficacy of Adebrelimab Combined With Chemotherapy After HIFU Induction Neoadjuvant Therapy HR+/HER2- Breast Cancer
To explore the efficacy and safety of adebrelimab combined with chemotherapy (epirubicin + cyclophosphamide →docetaxel) neoadjuvant therapy early HR+/HER2- breast cancer with high risk factors after the induction treatment of…
- Trial name
- NCT06470633
- Testing
- Adebrelimab, High Intensity Focused Ultrasoun（HIFU）, Cyclophosphamide
- Volunteers
- 29 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Stage I Mantle Cell Lymphoma, Stage II Contiguous Mantle Cell Lymphoma
Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
This phase II trial studies how well ofatumumab in combination with cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and dexamethasone alternating with ofatumumab in combination with cytarabine and methotrexate…
- Conditions
- Stage I Mantle Cell Lymphoma, Stage II Contiguous Mantle Cell Lymphoma, Stage II Non-Contiguous Mantle Cell Lymphoma, Stage III Mantle Cell Lymphoma
- Trial name
- NCT01527149
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Cytarabine
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- Roswell Park Cancer Institute
Multiple Myeloma
A Open-label Study of Ultra-High Dose Dexamethasone for Relapsed Multiple Myeloma
This is a phase II, open label, single-center study of ultra-high dose dexamethasone administered intravenously and orally as monotherapy for the treatment of relapsed multiple myeloma.
- Trial name
- UltraDex (NCT02402725)
- Testing
- Dexamethasone
- Where
- United States
- Sponsor
- Boston Medical Center
Breast Adenocarcinoma
Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer
This randomized phase III trial studies doxorubicin hydrochloride, cyclophosphamide, and paclitaxel to see how well they work with or without bevacizumab in treating patients with cancer that has spread to the lymph nodes (lymph…
- Trial name
- NCT00433511
- Testing
- Bevacizumab, Cyclophosphamide, Doxorubicin Hydrochloride
- Where
- 842 sites in United States, Peru and 1 more
- Volunteers
- 4,994 people
- Sponsor
- National Cancer Institute (NCI)
Malignant Melanoma
Phase II Trial of (IL-2) With Priming and (GM-CSF) in Patients With Advanced Melanoma
High-dose IL-2 treatment for metastatic melanoma has been approved by the FDA in 1998. Studies of GM-CSF plus IL-2 have not addressed the approved dose and schedule.
- Trial name
- NCT00616564
- Testing
- GM-CSF
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Mt. Sinai Medical Center, Miami
Melanoma (Skin)
High-Dose or Low-Dose Interferon Alfa Compared With No Further Therapy Following Surgery in Treating Patients With Stage III Melanoma
RATIONALE: Interferon alfa may interfere with the growth of cancer cells. It is not known whether giving high-dose or low-dose interferon alfa is more effective than no further therapy in treating patients with stage III…
- Trial name
- NCT00002763
- Testing
- recombinant interferon alfa
- Where
- 86 sites in Austria, Belgium and 19 more
- Volunteers
- 1,000 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Calcified Coronary Artery Disease (Grade 3)
A ComparIson of Strategies to PrepAre SeveRely CALCified Coronary Lesions
The objective of this prospective, multicenter, randomized, open-label trial is to evaluate the completeness of stent expansion following a strategy of lesion preparation with either a Super High-Pressure NC PTCA Balloon (OPN NC)…
- Trial name
- ISAR-CALC (NCT03487432)
- Testing
- Super High-Pressure NC PTCA Balloon (OPN NC), Scoring PTCA Balloon (NSE Alpha)
- Where
- 5 sites in Germany, Switzerland
- Volunteers
- 74 people
- Sponsor
- Deutsches Herzzentrum Muenchen
T Cell Lymphoma
Allo-HSCT as First-line Consolidation in High-risk PTCL
Results of conventional therapy in patients with peripheral T-cell lymphoma(PTCL) are poor. Allogeneic hematopoietic stem cell transplantation(allo-HSCT) gave excellent results in PTCL after failure of conventional therapy and in…
- Trial name
- NCT03672084
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Peking University People's Hospital
Recurrent or Metastatic Colorectal Cancer
A Phase I Trial of HDFL48 in Recurrent or Metastatic Colorectal Cancers
To determine the maximum tolerated dose and dose limiting toxicity of 5-FU and leucovorin with novel 48-hour infusion schedule, and to collect toxicity profile at different dose level of 5-FU/LV 48-hour infusion.
- Trial name
- NCT00155558
- Testing
- 5-Fluorouracil, Leucovorin
- Where
- Taiwan
- Volunteers
- 16 people
- Sponsor
- National Taiwan University Hospital
Ovarian Epithelial Cancer, Carcinoma in Situ
Early Detection of High Grade Ovarian Cancer Using Uterine Lavage EHUD Study and Duplex Sequencing
In Phase I the sponsor will systematically test conditions for lavage filtration that increase tumor cell fraction without reducing tumor mutation yield.
- Conditions
- Ovarian Epithelial Cancer, Carcinoma in Situ, Ovarian Cancer
- Trial name
- EHUD (NCT04823871)
- Testing
- Speiser-catheter for uterine and tubal lavage
- Where
- 9 sites in Austria, Czechia and 2 more
- Volunteers
- 406 people
- Sponsor
- Paul Speiser, Prof.MD,
CIN 2/3, HPV Infection
Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3)
This is a phase II double blind, placebo-controlled, randomized study of Artesunate vaginal inserts for the treatment of women who have cervical high grade intraepithelial neoplasia (CIN2/3).
- Conditions
- CIN 2/3, HPV Infection, Pre-Cancerous Dysplasia, Cervical Dysplasia
- Trial name
- ART-CIN_IIB (NCT04098744)
- Testing
- Artesunate vaginal insert
- Where
- 7 sites in United States
- Volunteers
- 78 people
- Sponsor
- Frantz Viral Therapeutics, LLC
Prostate Cancer Recurrent, Prostate Cancer
Biodistribution and Dosimetry of Ga-68 P16-093 in Prostate Cancer
Initial performance of Ga-68-P16-093 in prostate cancer patients including dosimetry and preliminary efficacy evaluation in BCR patients, and correlation of Ga-68-P16-093 uptake with tissue histopathology in intermediate to high…
- Trial name
- NCT03444844
- Testing
- Ga-68 P16-093 PET/CT scan
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Five Eleven Pharma, Inc.
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome
This phase I trial tests the safety, side effects, best dose, and effectiveness of 225Ac-DOTA-Anti-CD38 daratumumab monoclonal antibody in combination with fludarabine, melphalan and total marrow and lymphoid irradiation (TMLI)…
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT06287944
- Testing
- Actinium Ac 225-DOTA-Daratumumab, Biospecimen Collection, Bone Marrow Aspiration
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- City of Hope Medical Center
Prostate Cancer
Performance of Prostate MRI and Following Biopsy to Detect Prostate Cancer Recurrence After Focal Therapy
The management of localized prostate cancer remains controversial because of a risk of over diagnosis and over treatment. Focal therapy represents an approach to improve the therapeutic ratio of prostate cancer treatments.
- Trial name
- IRMProft (NCT04773821)
- Testing
- Targeted biopsies
- Where
- 11 sites in France
- Volunteers
- 260 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Lymphoma
Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma
The goal of this clinical research study is to learn about the safety and effectiveness of the combination of panobinostat, gemcitabine, busulfan, and melphalan, either with or without rituximab, in patients who have…
- Trial name
- NCT02961816
- Testing
- Palifermin, Panobinostat, Gemcitabine
- Sponsor
- M.D. Anderson Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.